These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

187 related items for PubMed ID: 10552153

  • 1. Future prospects in the chemotherapy of metastatic nonseminomatous testicular germ-cell cancer.
    Hartmann JT, Kuczyk MA, Kollmannsberger C, Kanz L, Bokemeyer C.
    World J Urol; 1999 Oct; 17(5):324-33. PubMed ID: 10552153
    [Abstract] [Full Text] [Related]

  • 2. Current trends in chemotherapy for metastatic nonseminomatous testicular germ cell tumors.
    Bokemeyer C.
    Oncology; 1998 Oct; 55(3):177-88. PubMed ID: 9560052
    [Abstract] [Full Text] [Related]

  • 3. The use of dose-intensified chemotherapy in the treatment of metastatic nonseminomatous testicular germ cell tumors. German Testicular Cancer Study Group.
    Bokemeyer C, Harstrick A, Beyer J, Metzner B, Rüther U, Hartmann JT, Holstein K, Derigs HG, de Wit R, Casper J, Schöffski P, Kührer I, Illiger HJ, Kempf B, Reichle A, Föller A, Hossfeld DK, Fischer JT, Berdel WE, Gerhartz HH, Kirchner H, Pflüger KH, Ostermann H, Kanz L, Schmoll HJ.
    Semin Oncol; 1998 Apr; 25(2 Suppl 4):24-32; discussion 45-8. PubMed ID: 9578059
    [Abstract] [Full Text] [Related]

  • 4. A randomized trial of cisplatin, etoposide and bleomycin (PEB) versus carboplatin, etoposide and bleomycin (CEB) for patients with 'good-risk' metastatic non-seminomatous germ cell tumors.
    Bokemeyer C, Köhrmann O, Tischler J, Weissbach L, Räth U, Haupt A, Schöffski P, Harstrick A, Schmoll HJ.
    Ann Oncol; 1996 Dec; 7(10):1015-21. PubMed ID: 9037359
    [Abstract] [Full Text] [Related]

  • 5. Diagnosis and treatment of patients with testicular germ cell cancer.
    Hartmann JT, Kanz L, Bokemeyer C.
    Drugs; 1999 Aug; 58(2):257-81. PubMed ID: 10473019
    [Abstract] [Full Text] [Related]

  • 6. Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group.
    Schmoll HJ, Kollmannsberger C, Metzner B, Hartmann JT, Schleucher N, Schöffski P, Schleicher J, Rick O, Beyer J, Hossfeld D, Kanz L, Berdel WE, Andreesen R, Bokemeyer C, German Testicular Cancer Study Group.
    J Clin Oncol; 2003 Nov 15; 21(22):4083-91. PubMed ID: 14568987
    [Abstract] [Full Text] [Related]

  • 7. Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group.
    de Wit R, Stoter G, Kaye SB, Sleijfer DT, Jones WG, ten Bokkel Huinink WW, Rea LA, Collette L, Sylvester R.
    J Clin Oncol; 1997 May 15; 15(5):1837-43. PubMed ID: 9164193
    [Abstract] [Full Text] [Related]

  • 8. High-dose sequential chemotherapy (HDS) versus PEB chemotherapy as first-line treatment of patients with poor prognosis germ-cell tumors: mature results of an Italian randomized phase II study.
    Necchi A, Mariani L, Di Nicola M, Lo Vullo S, Nicolai N, Giannatempo P, Raggi D, Farè E, Magni M, Piva L, Matteucci P, Catanzaro M, Biasoni D, Torelli T, Stagni S, Bengala C, Barone C, Schiavetto I, Siena S, Carlo-Stella C, Pizzocaro G, Salvioni R, Gianni AM.
    Ann Oncol; 2015 Jan 15; 26(1):167-172. PubMed ID: 25344361
    [Abstract] [Full Text] [Related]

  • 9. Chemotherapy in patients with metastatic or relapsed germ-cell tumours.
    Rick O, Siegert W, Beyer J.
    Cancer Treat Rev; 2001 Oct 15; 27(5):283-8. PubMed ID: 11871864
    [Abstract] [Full Text] [Related]

  • 10. Treatment of patients with cisplatin-refractory testicular germ-cell cancer. German Testicular Cancer Study Group (GTCSG).
    Bokemeyer C, Kollmannsberger C, Harstrick A, Beyer J, Gerl A, Casper J, Metzner B, Hartmann JT, Schmoll HJ, Kanz L.
    Int J Cancer; 1999 Dec 10; 83(6):848-51. PubMed ID: 10597209
    [Abstract] [Full Text] [Related]

  • 11. Improved long term survival of patients with metastatic nonseminomatous testicular germ cell carcinoma in relation to prognostic classification systems during the cisplatin era.
    Sonneveld DJ, Hoekstra HJ, van der Graaf WT, Sluiter WJ, Mulder NH, Willemse PH, Koops HS, Sleijfer DT.
    Cancer; 2001 Apr 01; 91(7):1304-15. PubMed ID: 11283931
    [Abstract] [Full Text] [Related]

  • 12. The role of paclitaxel in chemosensitive urological malignancies: current strategies in bladder cancer and testicular germ-cell tumors.
    Bokemeyer C, Hartmann JT, Kuczyk MA, Truss MC, Beyer J, Jonas U, Kanz L.
    World J Urol; 1996 Apr 01; 14(6):354-9. PubMed ID: 8986035
    [Abstract] [Full Text] [Related]

  • 13. Are 3 cycles of bleomycin, etoposide and cisplatin or 4 cycles of etoposide and cisplatin equivalent optimal regimens for patients with good risk metastatic germ cell tumors of the testis? The need for a randomized trial.
    Culine S, Theodore C, Terrier-Lacombe MJ, Droz JP.
    J Urol; 1997 Mar 01; 157(3):855-8; discussion 858-9. PubMed ID: 9072585
    [Abstract] [Full Text] [Related]

  • 14. Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial.
    Horwich A, Sleijfer DT, Fosså SD, Kaye SB, Oliver RT, Cullen MH, Mead GM, de Wit R, de Mulder PH, Dearnaley DP, Cook PA, Sylvester RJ, Stenning SP.
    J Clin Oncol; 1997 May 01; 15(5):1844-52. PubMed ID: 9164194
    [Abstract] [Full Text] [Related]

  • 15. Long-term survival of patients with recurrent or refractory germ cell tumors after high dose chemotherapy.
    Beyer J, Kingreen D, Krause M, Schleicher J, Schwaner I, Schwella N, Huhn D, Siegert W.
    Cancer; 1997 Jan 01; 79(1):161-8. PubMed ID: 8988741
    [Abstract] [Full Text] [Related]

  • 16. Treatment in germ cell tumours: state of the art.
    Tjan-Heijnen VC, Oosterhof GO, de Wit R, De Mulder PH.
    Eur J Surg Oncol; 1997 Apr 01; 23(2):110-7. PubMed ID: 9158183
    [Abstract] [Full Text] [Related]

  • 17. Intensive induction chemotherapy with CBOP/BEP in patients with poor prognosis germ cell tumors.
    Christian JA, Huddart RA, Norman A, Mason M, Fossa S, Aass N, Nicholl EJ, Dearnaley DP, Horwich A.
    J Clin Oncol; 2003 Mar 01; 21(5):871-7. PubMed ID: 12610187
    [Abstract] [Full Text] [Related]

  • 18. Treatment of patients with metastatic germ cell tumors relapsing after high-dose chemotherapy.
    Kollmannsberger C, Mayer F, Kuczyk M, Kanz L, Bokemeyer C.
    World J Urol; 2001 Apr 01; 19(2):120-5. PubMed ID: 11374314
    [Abstract] [Full Text] [Related]

  • 19. High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: a phase I/II study. The German Testicular Cancer Cooperative Study Group.
    Siegert W, Beyer J, Strohscheer I, Baurmann H, Oettle H, Zingsem J, Zimmermann R, Bokemeyer C, Schmoll HJ, Huhn D.
    J Clin Oncol; 1994 Jun 01; 12(6):1223-31. PubMed ID: 7911158
    [Abstract] [Full Text] [Related]

  • 20. High-dose chemotherapy with hematopoietic stem-cell support in germ-cell tumor patient treatment: the French experience.
    Fléchon A, Biron P, Droz JP.
    Int J Cancer; 1999 Dec 10; 83(6):844-7. PubMed ID: 10597208
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.